FDA OKs first biosimilar of Roche’s blockbuster AMD drug LucentisSamsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Share XFDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentishttps://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/
Europe has its first Lucentis biosimilar, Samsung Bioepis’ ByoovizNovartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission Share XEurope has its first Lucentis biosimilar, Samsung Bioepis’ Byoovizhttps://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/
